A Phase 1 Study of Arginase Inhibitor CB-1158 in Combination With Immune Checkpoint Therapy in Solid Tumors

Conditions:   Metastatic Cancer;   Solid Tumors;   Non-small Cell Lung Cancer;   Colo-Rectal Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Squamous-cell Carcinomas of the Head and Neck
Interventions:   Drug: CB-1158;   Drug: Nivolumab
Sponsor:   Calithera Biosciences, Inc
Recruiting - verified September 2016

http://ift.tt/2cTQz0G